ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0829

Adult Onset Still’s Disease: A Retrospective Study of Objective Manifestations and Outcomes
Abstract Number: 0830

Lymphopenia as a Marker of Disease Activity and Severity in Sarcoidosis
Abstract Number: 0831

Management of Hepatic Sarcoidosis, a Retrospective Analysis of Patients at a University Hospital
Abstract Number: 0832

Anti-NOR 90 Antibodies: What Is the Clinical Significance in Rheumatic Inflammatory Conditions?
Abstract Number: 0833

Disability Among Persons with Chronic Severe Back Pain: Results from a Nationally Representative Population Based Sample
Abstract Number: 0834

Use of the Routine Assessment of Patient Index Data 3 (RAPID3) Questionnaire in the Assessment of Chronic Lower Back Pain
Abstract Number: 0835

Temporal Trends in Prosthetic Joint Infection
Abstract Number: 0836

Bone Turnover and Physical Activity Before and After Anterior Cruciate Ligament Reconstruction
Abstract Number: 0837

Providers’ Adoption of 2017 Guidelines on DMARD Use Perioperatively for Elective Total Hip and Knee Arthroplasty at a Single Academic Center
Abstract Number: 0838

Is SARS-CoV-2 Associated with Worse Outcomes After Total Knee Arthroplasty?
Abstract Number: 0839

Association of Tibial Acceleration During Walking to Knee Pain and Loading in Adults with Knee Osteoarthritis
Abstract Number: 0840

Postoperative Risk of Immunosuppression in Rheumatic Disease Patients Undergoing Arthroscopy
Abstract Number: 0841

Relation of PainDETECT to Unpredictable Pain in People with or at Risk of Knee Osteoarthritis
Abstract Number: 0842

The Amount of Fluid in the Retrocalcaneal Area Negatively Correlates with Lower Extremity Function
Abstract Number: 0843

Racial Disparities in Patient Satisfaction Following Total Joint Arthroplasty: A Contemporary Trends Analysis from 2013-2021

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].